what would you tell week-1 you about ACHIEVE
what would you tell week-1 you about ACHIEVE. I would rather ask a basic question now than get this wrong quietly for two months.
Because it is not a peptide, it is not subject to the same degradation pathways, does not require the absorption enhancers used for oral peptides, and can be formulated as a conventional tablet.
Oral semaglutide is a peptide co-formulated with an absorption enhancer and carries food and water timing requirements. A small molecule does not have that constraint, which is the practical distinction.
Daily dosing gives a very different exposure profile from a weekly injectable: peaks and troughs within each day rather than a smoothed weekly curve.
That is everything I have. The rest is opinion and I have tried to keep it out.
best — the order this archive was captured in
It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a substantial medicinal chemistry achievement: getting a small molecule to activate a receptor evolved for a peptide ligand.
What analytical method was used — this is not the usual peptide assay question?
Cosigning on daily dosing. It changes the exposure profile and it changes adherence, in both directions.
Nothing containing this compound is approved by any regulator, and research-use-only material is not approved for human use.
Spent an evening reading about small-molecule agonism at a peptide receptor. Genuinely interesting engineering.
Compared milligram figures across two completely different molecule classes in a comment. Deserved the correction.
the tolerability profile reads broadly similar to the class
oral semaglutide is a peptide with an absorption enhancer, this is not that
Standing reminder: unapproved compound, research material is not for human use, and no schedules for other members.
Small fix — the two programme names got swapped upthread and it changes which population the figure came from.
do not assume reconstitution intuitions apply, there is nothing to reconstitute
daily dosing, not weekly, so the exposure profile is different
the manufacturing story is genuinely different from the injectables
oral semaglutide is a peptide with an absorption enhancer, this is not that
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Disagreeing with this bit: daily dosing is a different adherence problem, not a better one.
Agreed, and it is why the oral peptide comparison keeps misleading people.
Analytically this is a small-molecule identity and purity problem, not a peptide one. The methods, the impurity classes and the reference standards are all different.
That is a phase 2 result being quoted as though the programme had reported.
- 1oral semaglutide is a peptide with an absorption enhancer, this is not that10 comments in this branch · started by u/enzo_ferrari
- 2It is a non-peptide small-molecule agonist at the GLP-1 receptor. That is a…8 comments in this branch · started by u/lina_bruun